T2EVOLVE is proud to announce the creation of a new committee composed of European engineered T-cell experts. The first meeting took place October 7, 2021. With an experienced & multi-national panel, this committee will advise, guide, & support T2EVOLVE in elaborating standards for analytical practices in engineered T-cell therapies, from leukapheresis product to post-infusion monitoring of the patient.
